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The transmission of avian H5N1 influenza viruses to 18 humans in Hong Kong in 
1997 with six deaths established that avian influenza viruses can transmit to and cause 
lethal infection in humans. Concerns were raised about another global influenza 
pandemic because humans have absolutely no immunity against any H5 viruses. At 
present, vaccination remains the principal measure for preventing influenza and 
reducing the impact of epidemics. In this study, I investigated the use of 
microencapsulation in alginate matrix for antigen delivery. 
 
Bovine serum albumin (BSA) and partial purified hemagglutinin (HA) proteins were 
encapsulated in alginate matrix by electrostatic extrusion technique to form a delivery 
system which allowed for controlled release of protein. A positively charged needle 
with grounded collecting solution system was selected as the electrode configuration 
for the extrusion process. I found that applied voltage, flow rate, electrode spacing and 
needle size played their roles in electrostatic microcapsule formation and models were 
established between microcapsule size and two dominant factors, i.e., applied voltage 
and flow rate. As the voltage applied to the needle was increased, the formed droplets 
were reduced in size. However, any increase in applied voltage above its critical point 
did not result in much reduction in droplet size. Further reduction in droplet size 
would be achieved by reducing the flow rate of the polymer solution, which would 
give more time for counter ions to diffuse to droplet surface and reduce the surface 
tension. Meanwhile, either narrowing the electrode spacing or decreasing the needle 
size could also help reduce droplet size. 
 
 v
Alginate, a natural polysaccharide, was selected to form the polymeric matrix for 
antigen encapsulation, due to its excellent biocompatibility, biodegradability and non-
toxicity. Alginate can be ionically crosslinked by the addition of divalent cations, such 
as Ca2+, Sr2+, and Ba2+, in aqueous solution. However, the resulting Ca-alginate 
microcapsules are very porous. My study showed a quick release of BSA proteins in 
Tris-HCl buffer solution. Therefore, polymeric coatings are often applied to ensure 
better isolation and retention of the encapsulated material. Poly-L-lysine and chitosan 
are the most commonly used polycations for microcapsule production. My study 
favoured chitosan over poly-L-lysine due to its low cost, easy access and naturalness. 
In vitro results showed protein release was affected by microcapsules size, pH, protein 
loading, and release medium. It would be significantly delayed if chitosan coating 
were applied on the Ca-alginate microcapsules. Further investigations were needed to 
explore the in vivo function of alginate matrix, strengthen alginate matrix by Ba2+, 




Symbol   Description 
 
d  diameter of the droplet, m  
do   diameter of the droplet under gravity only, m  
db   diameter of the gel beads in the receiving solutions, m 
dc  internal diameter of the needle, m 
de   external diameter of the needle, m  
ds   diameter of the pendant droplet neck, m    
D  diffusion coefficient of the surfactant, m2/s  
Δx  characteristic diffusional length, m 
εo   permittivity of the vacuum (air), F/m 
F  Faraday constant, C/mol 
Fe   electric force under applied electrical potential, N  
g  gravity constant, N/kg  
γ  liquid surface tension, N/m 
γo  liquid surface tension (under gravity only or pure water), N/m 
γe  surface tension at its equilibrium value, N/m 
Γ  adsorption amount of a surfactant at the droplet surface, mol/m2
h   distance between the droplet and collecting solution, m 
js  flux of the surfactant into the surface, mol/m2⋅s 
jv   flow rate of the solution, m3/s 
k  fitting parameter 
K  electrical conductivity, (S/m) 
 vii
μ   viscosity of the solution, Pa⋅s 
qo   electrical charge accumulated, C 
ρd   density of the dispersed phase, kg/m3
τad  characteristic relaxation time of the adsorption, s 
τv  characteristic relaxation time of the formation of the drop, s 
U   applied electrical potential, V 




BCA  Bicinchoninic acid 
BSA   Bovine serum albumin 
CDC  Centers for Disease Control and Prevention 
DNA  Deoxyribonucleic acid 
FITC-BSA Bovine serum albumin-fluorescein isothiocyanate 
H5N1  Hemagglutinin type 5 & Neuraminidase type 1 
HA  Hemagglutinin 
HPAI  Highly pathogenic avian influenza 
M1  Matrix protein 1 
M2  Matrix protein 2 
NA  Neuraminidase 
NP  Nucleoprotein 
PLG  Polylactide-co-glycolides 
RNA  Ribonucleic acid 
vRNA  viral RNA 
mRNA  messenger RNA 
RNP  Ribonucleoprotein 
SDS-PAGE Sodium dodecyl sulfate - polyacrylamide gel electrophoresis  
SEM  Scanning electron microscope 
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CHAPTER 1 INTRODUCTION 
 
1.1 Motivation and objectives 
In 1997, an influenza virus (H5N1) known to infect only birds previously was found to 
infect human causing disease and death in Hong Kong and the outbreak involved 18 
patients with six deaths (Tam, 2002). The government of Hong Kong decided on 28 
December 1997, to cull all chickens in Hong Kong and 1.5 million of birds were killed 
from 29 to 31 December 1997. Since then, an epidemic of influenza in poultry, 
commonly referred to as “bird flu”, began sweeping through several countries in the 
Pacific Rim (Vietnam, Thailand, Japan, China, South Korea, Cambodia) in early 21st 
century. It caused serious financial damage, public health threat and mental distress to 
people in the region. Scientists also warned its potential to develop into another deadly 
global pandemic. World Health Organization (WHO) has urged both developed and 
developing countries to act swiftly and decisively to control and contain this outbreak. 
 
The most powerful thrust to the influenza control program focuses on vaccination 
(Straus, 1993). To curb spread of “bird flu”, Vietnam government plans to test 
vaccines in chickens and ducks from June to August 2005, leading to compulsory 
vaccination in high-risk areas in October. Ho Chi Minh City will conduct trial 
vaccination with 600,000 doses of Trovac avian influenza vaccine, produced by 
Merial France, while 2.7 million doses of a related Dutch vaccine will be tested 
elsewhere in the country, according to the official Vietnam News Agency. 
 
Most influenza vaccines are prepared from influenza virus strains grown in 
embryonated hens’ eggs. However, reactions are reported in some vaccinees given 
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whole, inactive virus vaccine; thus many contemporary vaccines are vaccines 
containing only the surface hemagglutinin (HA) and neuraminidase (NA) 
glycoproteins, termed subunit vaccines (Potter, 1994). However, subunit antigens 
alone are usually only weak immunogens and require an adjuvant or carrier system to 
induce protective immunity. The quality of the resulting antibody-and/or cell-mediated 
immune response and its magnitude depends on appropriate antigen processing and 
the cytokine profile generated by the combined action of the antigen and the adjuvant 
(Felnerova et al., 2004). 
 
Many vaccine delivery systems have been proposed to provide sustained release 
and/or to increase the immune response. One approach to the development of delivery 
system for vaccines involves the use of polymer encapsulation of antigens (Singh and 
O’Hagan, 1998). The polymeric microcapsules that protect antigen from acidic and 
enzymatic degradation in the gastrointestinal tract also provide a stable vaccine 
vehicle with extended shelf life. Once encapsulated, antigen is released from the 
microspheres by diffusion through matrix pores and by matrix degradation (Morris et 
al., 1994). 
 
A number of different polymers have been evaluated for the development of oral 
vaccines, including naturally occurring polymers (e.g. starch, alginates and gelatin) 
and synthetic polymers (e.g. polylactide-co-glycolides (PLG), polyanhydrides and 
phthalates). In material selection, of primary concern are considerations of toxicity, 
irritancy and allergenicity, and the need for a biodegradable or a soluble coating. 
Usually, natural polymers are preferred. The advantages of using natural polymers 
include their low cost, biocompatibility and aqueous solubility (Singh and O’Hagan, 
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1998). Among all the natural polymers, alginate is the most commonly employed 
polymer for cell encapsulation (Gerbsch and Buchholz, 1995). Many studies have also 
been carried out using alginate matrix as a vaccine delivery system (Kwok et al., 1989; 
Bowersock et al., 1994 and 1996; Wee et al., 1995). The main advantages of using 
alginate microcapsules for antigen delivery are the low cost of polymer, good 
biocompatibility and ease of preparation (Singh and O’Hagan, 1998). 
 
In my study, Bovine serum albumin (BSA) and partial purified hemagglutinin (HA) 
proteins were encapsulated in alginate matrix by electrostatic extrusion technique to 
form a delivery system which allowed for controlled release. The objectives of this 
study were: 
— Encapsulate antigens (BSA or HA) in alginate matrix by electrostatic extrusion 
— Study the governing factors of electrostatic extrusion process 
— Study the in vitro release of BSA or HA from Ca-alginate matrix 
— Study the effect of chitosan coating on the microcapsule structure and antigen 
release 
 
1.2 Organization of the thesis 
This thesis is divided into five chapters. Chapter 1 is an introduction to the motivation 
and objectives of the project, followed by a description of the organization of the 
thesis. Chapter 2 is a literature review on the influenza A H5N1 virus, vaccination, 
microencapsulation by electrostatic extrusion and formation of alginate matrix. In 
Chapters 3, materials and methods used in this study are described. The experimental 
results as well as the discussion are presented in Chapter 4. Finally, a summary of the 
findings in this study and recommendations for future research are given in Chapter 5.  
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CHAPTER 2 BACKGROUND AND LITERATURE REVIEW 
 
2.1 Influenza and H5N1 virus 
2.1.1 Influenza and its virus 
According to World Health Organization (WHO, 2003), influenza is caused by a virus 
that attacks mainly the upper respiratory tract – the nose, throat and bronchi and rarely 
also the lungs. The infection usually lasts for about a week. It is characterized by 
sudden onset of high fever, myalgia, headache and severe malaise, non-productive 
cough, sore throat, and rhinitis. Most people recover within one to two weeks without 
requiring any medical treatment. In the very young, the elderly and people suffering 
from medical conditions such as lung diseases, diabetes, cancer, kidney or heart 
problems, influenza poses a serious risk. In these people, the infection may lead to 
severe complications of underlying diseases, pneumonia and death. 
 
Influenza viruses (Fig. 2.1) belong to the family Orthomyxoviridae and are separated 
into types A, B and C according to antigenic differences in their respective 
nucleocapsid (WHO, 2002).  
 
 
Figure 2.1 Microscopy image of influenza virus (Stannard, 1995) 
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There are significant differences in genetic organization, structure, host range, 
epidemiology, and clinical characteristics between the three influenza virus types, 
which are summarized in Table 2.1. 
 
Table 2.1 Differences between influenza A, B, and C viruses (Treanor, 1999) 
 Influenza A Influenza B Influenza C 
Genetics 8 gene segments 8 gene segments 7 gene segments 
Structure 10 viral proteins 
M2 protein unique 
11 viral proteins 
NB protein unique 
9 viral proteins 
HEF protein unique 
Host range Humans, swine, 
equine, avian, 
marine mammals 
Humans only Humans and swine 
Epidemiology Antigenic shift and 
drift; Drift is 
generally linear 
Antigenic drift 
only; More than 





Clinical features May cause large 
pandemics with 
significant 




to elderly or those 
at high risk; 




As shown in Fig. 2.2, influenza viruses are negative-strand RNA viruses with a 
segmented genome. The eight RNA segments of influenza viruses (seven for influenza 
C) are independently encapsulated by the viral nucleoprotein (NP) and each segment 
is associated with a polymerase complex. The subviral particle consisting of viral 
RNA (vRNA), NP and polymerase complex is called ribonucleoprotein (RNP) particle. 
The RNP particles are located inside a shell of M1 protein which lines with the viral 
lipid membrane. The surface of the particle contains three kinds of spike proteins: 





Figure 2.2 A schematic drawing of influenza virus structure 
 
Further classification of type A virus into subtype is dependent on differences in the 
HA and NA antigens, and 16 HA and 9 NA subtypes are known so far. Influenza A 
viruses are distinguished according to a formula, such as A/Hong Kong/1/68 (H3N2): 
this designation means that the virus is type A, was isolated in Hong Kong, is the first 
laboratory isolate made in 1968, and has the HA and NA molecule forms HA3 and 
NA2, respectively (Potter, 1994). 
 
The influenza virus replicates by entering a host cell and using this cell's resources to 
produce hundreds of copies of the viral RNA (Fig. 2.3). The virus attaches to the 
outside of the host cell and its RNA enters into the cell. Fusion and uncoating events, 
which are pH dependent, result in the release of the viral genomes into the cytoplasm. 
They are then imported into the nucleus for replication. Positive-sense viral messenger 









M2 Protein  
(only on type A) 
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synthesis. Some of the proteins are imported into the nucleus to assist in viral RNA 
replication and packaging. In this way, the virus takes over the cell's productivity. 
Now, instead of producing only new cellular material, the cell produces hundreds of 
new virus particles. Those particles are eventually released from the cell and drift off. 
 
 
Figure 2.3 Replication cycle of influenza virus (Levine, 1992) 
 
2.1.2 Influenza pandemic and its impact 
Influenza viruses can change in two different ways. 
— Antigenic drift, the HA and NA proteins of the influenza virus can undergo minor 
changes or mutations, leading to new strains. It happens continually over time, and 
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produces new virus strains that may not be recognized by antibodies to earlier 
influenza strains. 
— Antigenic shift, it is an abrupt, major change in the influenza A viruses, resulting in 
a new influenza virus that can infect humans and has a new HA or HA and NA 
protein combination that has not been seen in humans for many years. 
 
Antigenic shift results in a new influenza A subtype. If a new subtype of influenza A 
virus is introduced into the human population, if most people have little or no 
protection against the new virus, and if the virus can spread easily from person to 
person, a pandemic may occur. 
 
According to WHO (2003), three times in the last century, the influenza A viruses 
have undergone major genetic changes mainly in their H-component, resulting in 
global pandemics and large tolls in terms of both disease and deaths. The most 
infamous pandemic was “Spanish Flu” which affected large parts of the world 
population and is thought to have killed at least 40 million people in 1918-1919. More 
recently, two other influenza A pandemics occurred in 1957 (“Asian influenza”) and 
1968 (“Hong Kong influenza”) and caused significant morbidity and mortality 
globally. Most recently, limited outbreaks of a new influenza subtype A (H5N1) 
directly transmitted from birds to humans have occurred in Hong Kong Special 
Administrative Region of China in 1997 and 2003.  
 
According to Centers for Disease Control and Prevention (CDC), many scientists 
believe it is only a matter of time until the next influenza pandemic occurs (U.S. CDC, 
2005a). The severity of the next pandemic cannot be predicted, but modeling studies 
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suggest that its effect in the United States could be severe. In the absence of any 
control measures (vaccination or drugs), it has been estimated that in the United States 
a “medium–level” pandemic could cause 89,000 to 207,000 deaths, between 314,000 
and 734,000 hospitalizations, 18 to 42 million outpatient visits, and another 20 to 47 
million people being sick. Between 15% and 35% of the U.S. population could be 
affected by an influenza pandemic, and the economic impact could range between 
$71.3 and $166.5 billion. 
 
2.1.3 Avian influenza (Bird flu) and H5N1 virus 
Avian influenza (Bird flu) is an infection caused by avian influenza viruses. These flu 
viruses occur naturally among birds (U.S. CDC, 2005b). All birds are thought to be 
susceptible to infection with avian influenza, though some species are more resistant 
to infection than others. Infection causes a wide spectrum of symptoms in birds, 
ranging from mild illness to a highly contagious and rapidly fatal disease resulting in 
severe epidemics. The latter is known as “highly pathogenic avian influenza” (HPAI). 
This form is characterized by sudden onset, severe illness, and rapid death, with a 
mortality that can approach 100%. 
 
According to WHO (2004), fifteen subtypes of influenza virus are known to infect 
birds, thus providing an extensive reservoir of influenza viruses potentially circulating 
in bird populations. Of the 15 avian influenza virus subtypes, H5N1 is of particular 
concern for several reasons. H5N1 mutates rapidly and has a documented propensity 
to acquire genes from viruses infecting other animal species. Its ability to cause severe 
disease in humans has now been documented on several occasions. In addition, 
laboratory studies have demonstrated that isolates from this virus have a high 
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pathogenicity and can cause severe disease in humans. Birds that survive infection 
excrete virus for at least 10 days, orally and in faeces, thus facilitating further spread at 
live poultry markets and by migratory birds. 
 
H5N1 virus demonstrated a capacity to directly infect humans in 1997, and succeeded 
again in Viet Nam in January 2004 (WHO, 2004). The spread of infection in birds 
increases the opportunities for direct infection of humans. If more humans become 
infected over time, the likelihood also increases that humans, if concurrently infected 
with human and avian influenza strains, could serve as the “mixing vessel” for the 
emergence of a novel subtype with sufficient human genes to be easily transmitted 
from person to person. Such an event would mark the start of an influenza pandemic. 
 
2.1.4 Prevention and treatment 
Several measures can help minimize the global public health risks that could arise 
from large outbreaks of highly pathogenic H5N1 avian influenza in birds. An 
immediate priority is to halt further spread of epidemics in poultry populations. This 
strategy works to reduce opportunities for human exposure to the virus. Vaccination of 
persons at high risk of exposure to infected poultry, using existing vaccines effective 
against currently circulating human influenza strains, can reduce the likelihood of co-
infection of humans with avian and influenza strains, and thus reduce the risk that 
genes will be exchanged. Workers involved in the culling of poultry flocks must be 
protected, by proper clothing and equipment, against infection. These workers should 




Vaccination is the principal measure for preventing influenza and reducing the impact 
of epidemics. Various types of influenza vaccines have been available and used for 
more than 60 years. They are safe and effective in preventing both mild and severe 
outcomes of influenza (WHO, 2002).  
 
The major treatment for influenza infections are the time-proven ones involving 
hydration, rest, and antipyretics, especially acetaminophen rather than aspirin (Straus, 
1993). Antiviral drugs for influenza are an important adjunct to influenza vaccine for 
the treatment and prevention of influenza. When taken before infection or during early 
stage of the disease (within two days of illness onset), antivirals may help prevent 
infection, and if infection has already taken hold, their early administration may 
reduce the duration of symptoms by one to two days (WHO, 2003). 
 
2.2 Vaccination through a delivery system 
Vaccines against influenza have been around for 60 years. The antigens of the 
influenza virus particle which stimulate immunity to subsequent infection have been 
identified. The results of challenge studies indicated that immunity is induced by the 
host responses to the virus haemagglutinin (HA) and, to a lesser extent, to the 
neuraminidase (NA). Therefore, antibody against HA is the most important 
component in the protection against influenza viruses (Potter, 2000). 
 
There are four types of influenza vaccines currently available: 
— Whole virus vaccines, these are the first influenza vaccines to be produced. The 
currently circulating strain of influenza is inoculated into embryonated eggs, 
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harvested 2-3 days later and inactivated. However, systemic reactions, such as 
fever, headache and muscle pain have shown in some vaccinees.  
— Split virus vaccines, these are inactivated vaccine particles disrupted by 
detergents. Fewer side effects have shown while retaining effectiveness. 
— Subunit virus vaccines, these are vaccines containing only purified surface 
antigens (HA and NA). They are often used in aqueous suspension or may be 
absorbed to carriers such as alhydrogel. Vaccinees given subunit vaccines 
experience fewer reactions than those who taken the pervious two vaccines. 
— Live attenuated vaccines, these are produced by reassortment of wild-type strains 
of interest with carefully characterized attenuated strains. They will mimic 
pathogen infection to a large extent, but without causing disease. However, they 
can be dangerous to immuno-compromised individuals and may cause disease in 
otherwise healthy individuals. Other basic problems also remain particularly in the 
area of purification. The vaccine must also be shown to be attenuated and safe.  
 
Subunit virus vaccines were chosen in my study based on the above characteristics. 
Besides these existing vaccines, some researchers have also proposed a DNA-based 
vaccination technique (Tang et al., 1992), which is very much an approach for the 
future. The first clinical trials of such a vaccine for influenza have begun and there is a 
need for regulatory authorities worldwide to consider the requirements necessary for 
assuring the quality of these vaccines (Levandowski et al., 1996). Others prefer 
vaccination through a delivery system. For example, many researchers explored the 
adjuvanting properties of adsorbed lactide microparticulate vaccines (Wood et al., 
1996; Coombes et al., 1998); some evaluated polymeric microspheres as an oral 
antigen delivery system for immunization with influenza virus (Moldoveanu et al, 
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1993); others even suggest microencapsulated influenza antigen may have potential 
for a single dose vaccine delivery system with adjuvant properties (Hilbert et al., 
1999). 
 
2.3 Common microencapsulation techniques 
Microparticles prepared from certain polymers have the capacity to encapsulate and to 
surface adsorb influenza virus (Wood et al., 1996). Generally, microencapsulation 
involves two steps: drop formation (discrete droplet formation or emulsification), 
followed by droplet solidification (gelation, membrane formation, or other means) 
(Poncelet et al., 1999a). The most common techniques in microencapsulation are listed 
as follows. 
 
2.3.1 Solvent evaporation/extraction  
 
 




Solvent evaporation is the most widely used method for the preparation of 
microparticles with entrapped antigens (Singh and O’Hagan, 1998). The method is 
usually based on the formation of a multiple emulsion (water-in-oil-in-water or w/o/w) 
from which the oil phase (organic solvent) is evaporated and/or extracted to yield free 
flowing microcapsules, as shown in Fig. 2.4. 
 
This technique is based on the evaporation of the internal phase of an emulsion by 
agitation (Benoit et al., 1996). Initially, the polymeric supporting material is dissolved 
in a volatile organic solvent. The active drug to be encapsulated is then dispersed or 
dissolved in the organic solution to form a suspension, an emulsion or a solution.  
Next, the organic phase is emulsified under agitation in a dispersing phase consisting 
of a nonsolvent of the polymer, which is immiscible with the organic solvent, and 
contains an appropriate tensioactive additive. Once the emulsion is stabilized, 
agitation is maintained and the solvent evaporates after diffusing through the 
continuous phase. Finally, the microcapsules are filtered, dried and characterized after 
the removal of the solvents. 
 
The organic solvent of the dispersed phase of the emulsion can also be eliminated in 
two steps: 1) Diffusion of the solvent in the dispersing phase or solvent extraction; 2) 
Elimination of the solvent at the dispersing phase-air interface or solvent evaporation.  
In theory, if one uses a continuous phase which will immediately extract the solvent of 
the dispersed phase, the evaporation stage is no longer necessary (Benoit et al., 1996). 
In practice, this can be achieved by using large volumes of dispersing phase with 




The specific organic solvent, temperature of solvent evaporation, rate of agitation, 
volume of organic phase per unit volume of aqueous phase, nature and amount of 
emulsifier dissolved in the aqueous phase, polymer structure and molecular weight, 
and antigen solubility all influence the final microcapsule obtained. Very small 
microcapsules can be produced with this technique, but the size dispersion is generally 
larger than with the extrusion techniques (Poncelet and Neufeld, 1996). Another 
potential problem is the removal of solvent contaminants from the final microcapsules 
becomes more difficult as microcapsule size decreases.  
 
2.3.2 Phase separation 
Polymer phase separation, in nonaqueous media, by nonsolvent or polymer addition, 
also referred to as coacervation, is an excellent technique for the entrapment of water-
soluble drugs such as peptides, proteins, or vaccines (Benoit et al., 1996). 
 
This technique utilizes solubilized polyesters and antigen which are then mixed with 
salts, non-solvents or, more commonly, with an incompatible second polymer 
resulting in a separation of the polyester phase that engulfs the antigen particles 
(Deasy, 1988). The liquid-polyester/antigen phase is desolvated and solidified by the 
addition of excess non-solvent at low temperatures.  
 
Phase separation technique may protect antigens from being altered by exposure to 
heat or from their partitioning out into dispersing phases. However, this approach is 
limited to antigens which remain insoluble in the organic solvent used to dissolve the 
polyester. And residual solvent concentrations in resulting microcapsules can be very 
high, especially when heptane is chosen as the hardening agent (Müller et al., 1993).  
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2.3.3 Spray drying  
Spray drying is widely used in the chemical, pharmaceutical, and food industries 
(Nielsen, 1982). The principle of spray drying is the atomization of a solution by 
compressed air or nitrogen through a desiccating chamber and drying across a current 
of warm air. Knowledge of copolymer/antigen suspension rheology and nozzle design 
is used to control the microcapsule size and shape. Particle size distributions are 
usually monodispersed with a Gaussian distribution more or less depending on the 
pulverizing head employed (e.g., pneumatic atomizer, disc) and the other parameters 
such as, pressure of compressed air, internal diameter of the atomizer, viscosity, and 
flow rate of the solution (Benoit et al., 1996). One particular advantage for this 
technique is, residual levels of organic solvents are less than those from emulsification 
and evaporation techniques. However, there is only 20-30% core loading capacity for 
most spray-dried capsules. 
 
2.3.4  Extrusion 
The above three methods involve organic solvents and/or extreme temperature or pH 
conditions which could inactivate or damage the materials being encapsulated. An 
alternative approach is the ionic cross-linking of polyelectrolytes with counterions 
whereby one of the polyions containing a biomaterial is extruded as droplets into a 
solution where the droplets gel and these droplets are subsequently coated by another 
polyion (Poncelet et al., 1992; Bugarski et al., 1993; Daly and Knorr, 1988). 
 
Various extrusion methods proposed in the literature are summarized in Table 2.2, and 




Table 2.2 Methods in droplet extrusion (Dulieu et al., 1999) 
Extrusion methods 
Droplet formation Jet breakage 
• Under gravity 
• Under coaxial flow 
• Under electrostatic potential 
• By vibrating device 




Figure 2.5 Extrusion devices (Dulieu et al., 1999) 
 
2.3.4.1 Extrusion under simple gravity  
The simplest method to form individual droplets is to let a liquid droplet fall from the 
tip of a needle under simple gravity, as shown in Fig. 2.5 A. In this scenario, a pendant 
droplet is formed by the flow of a liquid through a needle, and continuously grows 
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until its mass reaches a critical value, when the droplet detaches from the tip of the 
tube and falls into a collecting solution. 
 
This method is often limited to a laboratory scale, due to a restriction on flow rate to 
prevent jet formation. The production capacity is limited by the speed of droplet 
formation at the tip of the needle, usually at an order of magnitude of ml/h. The other 
limitation is the large diameter of the beads, typically 2 to 3 mm, even for very small 
needle diameters. It compromises its application potential, as microcapsules with 
diameters larger than 1mm often induce significant mass transfer limitations and 
heterogeneous cell distribution within the beads (Groboillot et al., 1994). 
 
2.3.4.2 Extrusion under coaxial air or liquid flow 
The application of a coaxial air jet around the needle has been proposed by Lane (1947) 
to increase the force acting on nascent drops (Fig. 2.5 B). Charwat (1977) replaced the 
air by a liquid jet, permitting a better control of the viscosity, surface tension, and 
density of the entraining phase, through selection of an appropriate liquid. 
 
Both methods produce beads or microcapsules ranging from a few micrometers to one 
millimetre. However, the flow rate remains very limited, to less than 30 ml/h, to avoid 
formation of a liquid jet. And the size dispersion increases drastically when the droplet 
diameter is decreased (Poncelet et al., 1993). For these reasons, the coaxial fluid jet 
systems have not been considered for scale-up. Even on the laboratory scale, this 





2.3.4.3 Extrusion under electrostatic potential  
Droplet formation is greatly improved by replacing the drag force with a high 
electrostatic potential between the needle and the collecting solution (Burgarski et al., 
1993, 1994a; Poncelet et al., 1994). Electric potential may be applied between the 
needle and a stainless steel ring placed below the needle, as shown in Fig. 2.5 C. 
Under suitable conditions, the electrostatic pressure at the surface forces the liquid 
drop into a cone shape. Surplus charge is ejected by the emission of charged droplets 
from the tip of the liquid. The emission process depends on such factors as the needle 
diameter, distance from the collecting solution, and applied voltage (Nawab and 
Mason, 1958). Two primary advantages of electrostatic droplet generation, over, for 
example, an air jet extruder, are the production of much smaller beads with 
conventional needles and ease of bead size control by simply varying the applied 
potential (Goosen et al., 1997a). However, satellite peaks may be observed in the size 
distribution profile. Satellites are formed by breakage of the fine filament between the 
droplet and the needle tip just before separation, resulting in secondary peaks. Though 
the flow rate is still limited by the formation of the jet, electrostatic extrusion is a 
promising technique to obtain small microdroplets (down to 200 μm), at least at 
laboratory scale (Dulieu et al., 1999). Details of this technique will be discussed later. 
 
2.3.4.4 Jet breakage by vibration  
If liquid exceeds a certain velocity, it exits from the needle as a jet. Rayleigh (1878) 
showed that if an external wave of the natural frequency is applied to the jet, the jet 
breaks into monodispersed droplets (Fig. 2.5 D). This method is one of the most 
efficient techniques to produce large capsules (1 to 3 mm) with a narrow size 
distribution. A multi-nozzle system would enable production in the order of hundreds 
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of liters per hour. However, it appears more difficult to use this process for 
microcapsules less than 800 μm in diameter (Dulieu et al., 1999). 
 
2.3.4.5 Jet breakage by rotating systems  
To overcome the limitations of vibrating system, Prusse et al. (1997) proposed a 
rotating device to cut the jet into small droplets, as shown in Fig. 2.5 E. The diameter 
of the cutting wires is the main parameter determining the effectiveness of this method.  
 
Rotating jet breakage appeared to be an easy, efficient, and scalable device for 
producing large quantities of relatively small microcapsules with narrow size 
distribution (Dulieu et al., 1999). 
 
2.4 Electrostatic extrusion 
Electrostatic extrusion is a novel extrusion technique that uses electrostatic forces to 
disrupt a liquid surface at the capillary/needle tip forming a charged stream of small 
droplets (Nedovic et al., 2001). A polymer solution is extruded through a charged 
needle. The collecting solution directly beneath the needle is either grounded or has a 
charge opposite to that of the needle. As the polymer solution passes through the 
needle it accumulates charge and droplets formed at the end of the needle are pulled 
off by the electrostatic attractive force between the needle and the collecting solution. 







2.4.1 Droplet formation under electrostatic potential 
2.4.1.1 Size of droplets under simple gravity 
As shown in Fig. 2.6, under simple gravity, the droplet diameter, do, may be computed 
by equalizing the gravity force with the product of the interfacial tension, γο, and the 
perimeter of the tip, πds (Tate’s law): 
 
 
Figure 2.6 Droplet formation under simple gravity (Poncelet et al., 1999b) 
 
osdmg γπ=   or osd3o dgd6 γπρ
π =     (2.1) 
Where, g is the gravity constant, 
ds is the diameter of the pendant droplet neck, which is approximately equal to    
the external diameter of the needle de, 
γο is the liquid surface tension under gravity only, assumed equal to pure water, 
ρd is the density of the dispersed phase,  








doso )g/d6()g/d6(d ργργ ≈=     (2.2) 
However, the diameters db of the microcapsules in the collecting solutions may differ 
from the diameters of the falling droplets because of their contraction or swelling in 
the course of gelling or complex formation processes (Poncelet et al., 1999b) 
 
2.4.1.2 Size of droplets in an electric field 
According to Poncelet et al. (1999b), under an electric filed (Fig. 2.7), the condition 
for the mechanical equilibrium of a pendant droplet may be written as: 
)(UdFmg se γπ=+        (2.3) 
Where, Fe is the electric force under applied electrical potential U, 
 γ(U) is the surface tension of droplet under applied electrical potential U. 
 
 
Figure 2.7 Effect of electric field on the droplet formation (Poncelet et al., 1999b) 
 
For a single needle situated in the proximity of an infinite plane electrode 




2222 )2/()/()2/)(4/1( UhdddhqF coooe πεπε ≅≅    (2.4) 
Where, εo is the permittivity of the vacuum (air), 
 qo is the electrical charge accumulated, and qo = 2πεodcU, 
 h is the distance between the droplet and the plane electrode, 
 dc is the internal diameter of the needle, 
 U is the applied electrical potential. 
 
And according to Lippman’s theory of electrocapillarity, the equilibrium surface 
tension γ of the charged surface of a liquid droplet decrease with increasing electrical 
potential U as: 
)]/(1[)/1()( 222 croocoo UUdUkU −=−= γγεγγ    (2.5) 
Where, ooccr kdU εγ /=        (2.6) 
k ≤ 1, is the fitting parameter which accounts for the geometrical and kinetic 
approximations. 
By combining equations (2.3), (2.4), (2.5) and (2.6), I can have, 
3/12
/ })/](1[1{ crhdo UUdd α+−=      (2.7) 
Where, 222/ )2/()/( Uhddd chd =α      (2.8) 
As αd/h << 1, it may be estimated as, 
3121 /])/([)( cro UUdUd −≅       (2.9) 
Therefore, increasing the electrostatic potential, U, to a critical value, Ucr, leads to a 
decrease in the droplet size, d. Near Ucr, the surface tension becomes negligible and 
the liquid droplet becomes unstable. Further increase in U results in the formation of 
unstable jets, and the size of the droplets become quasi independent of the applied 
electric potential (Poncelet et al., 1999a). 
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2.4.1.3 Effect of kinetic effect on droplet formation process 
 
 
Figure 2.8 Effect of kinetic factors on droplet formation (Poncelet et al., 1999b) 
 
As shown in Fig. 2.8, Poncelet et al. (1999b) also discovered that, at a given value of 
solution flow rate jv, the rate of increasing the area A of the droplet surface may be 
expressed from the geometrical considerations as 
v/d)j(tA/ 4dd =         (2.10) 
Where, d is the effective droplet diameter at the time t, 
 jv is the flow rate of the solution. 
 
The adsorption amount of a surfactant at the droplet surface being defined as Γ = ms/A 








   (2.11) 
Where,  (mol mt)/m/A)( ( j ss dd1= -2 s-1) is the flux of the surfactant into the 
surface under the assumption of its irreversible adsorption, 
 sad j/Γτ = is characteristic relaxation time of the adsorption, 
 vv jV /=τ  is characteristic relaxation time of the formation of the droplet. 
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While according to Gibbs, the variation of the surface tension Δγ is proportional to the 
adsorption amount of surfactants, Γ, one may conclude that for dΓ/dt > 0 the surface 
tension will decrease tending to its equilibrium value γe at τv >> τad. In the case of 
dΓ/dt < 0, the surface tension will increase and tend to its maximal value γo (surface 
tension of pure water) at τv << τad.  
 
The characteristic time τad of the adsorption by diffusion may be estimated as 
D2/dD2/ΔxΓ/jτ 22sad ===       (2.17) 
Where, Δx is the characteristic diffusional length, 
d is the diameter of the droplet, 
D is the diffusion coefficient of the surfactant. 
 
Therefore, for low molecular weight ions (e.g., Na+), in the absence of an electric field, 
the diffusion coefficient D is around 10-8 m2 s-1. The characteristic time τad is much 
larger than τv. A very limited amount of surface active material will have time to reach 
the surface during droplet formation. The surface tension γ will then mainly be equal 
to the pure water γo. When subject to an electric field, the diffusion coefficient D of 
ionic surfactants is increased in the proportion of RTUFΔ , where F is the 
Faraday constant. The surface tension γ will be defined by equation (2.5), and droplet 
size will follow equation (2.9). However, for macromolecules (polymers), the 
diffusion coefficient D may be much smaller. Even under an electric filed, the ratio 
τad/τv remains large. Therefore, the surface tension would remain near the value of the 





— Dripping mode, under this mode, the droplet will grow until its weight overcomes 
the net vertical component of the surface tension force. At this point the liquid 
nearest the needle forms a neck, which eventually ruptures, thereby allowing the  
There are mainly two spraying modes in my study: dripping mode and cone-jet mode. 
 
The droplet can exit the needle in various modes (Table 2.3). According to Sample 
and Bollini (1972), when the spraying configuration is highly symmetric, and under 
certain conditions of liquid pressure and applied voltage, the spraying process can be 
somewhat regular and periodic.  
2.4.2 Modes of electrostatic dispersion 
 εo is the permittivity of the vacuum (air), 
Where, ρd is the density of the dispersed phase, 
If δμ >> 1, then d ∝ jv1/2      (2.20) 
If δμ << 1, then d ∝ jv1/3      (2.19) 
For 
Meanwhile, Gañán-Calvo et al. (1997) developed scaling laws for droplet size 
estimation in electrical field. They defined a dimensionless viscous parameter δμ and 








jv is the flow rate of the solution. 
d is the diameter of the droplet, 
μ is the viscosity of the solution, 
K is the electrical conductivity, 
γ is the liquid surface tension, 

















Table 2.3 (cont’d) Characteristic features of the modes of electrostatic dispersion (Jaworek and Krupa, 1999) 
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main part of the drop to fall from the needle. When a dc voltage is applied to the 
needle, electric field between the needle and the plate causes a rise in the emission 
frequency and a reduction in drop size. 
— Cone-jet mode, for some liquids, the application of a sufficiently high electric 
field causes the convergence of the liquid jet into a conical shape, known as the 
Taylor cone, based on the pioneering work of Taylor (1964). In this case, the 
droplets detach from the tip of the cone, rather than from the needle, leading to the 
formation of a steady stream of fine droplets. 
 
2.4.3 Governing factors on microcapsule formation 
Many researchers believed parameters such as applied voltage, needle size, electrode 
spacing, polymer concentration, flow rate and geometry played theirs roles in 
electrostatic microcapsule formation (Bugarski et al. 1994b; Klokk and Melvik, 2002). 
It has been proposed that the reduction in bead size with increasing potential is 
primarily a result of a fall in the surface tension of the droplets generated at the needle 
tip (Dulieu et al., 1999). However, any increase in applied potential above its critical 
point did not result in reduction in droplet size. Further reduction in microbead size 
could be achieved by decreasing the needle size or reduce the electrode spacing 
(Bugarski et al., 1994b; Goosen et al., 1997b; Klokk and Melvik, 2002; Nawab and 
Mason, 1958). Meanwhile, as the voltage was increased above Ucr, a high surface 
charge and an electric field on the surface of needle tip gave rise to a mechanical force 
causing needle vibration and resulting in an oscillating thread-like filament. The 
greatest decrease in microbead size was observed when natural needle oscillation 




Klokk and Mevik (2002) also found that, an increase in concentration of the polymer 
solution caused an increase in bead diameter; furthermore, the bead size was more 
strongly correlated to solution viscosity than to the actual polymer concentration. The 
standard deviation also decreased at the lower polymer concentration due to a more 
uniform bead size distribution (Bugarski et al., 1994b; Goosen, 1996).  
 
It seemed impossible to compensate for the higher polymer solution concentration by 
increasing the electrostatic voltage further; however, reducing the flow rate of the 
polymer solution could amend the effect of higher solution viscosity (Klokk and 
Melvik, 2002). Because low flow rate will give more time for counter ions to diffuse 
to droplet surface and reduce the surface tension (Hallé et al., 1994). 
 
Bugarski et al. (1994a) also investigated with three types of electrode configurations: a 
parallel plate; a positively charged needle; and a grounded needle with alginate as the 
polymer. They concluded that the smallest droplet size was produced with the 
positively charged small diameter needle.  
 
2.5 Alginate as a vaccine delivery system 
In the past, a whole range of different polymeric materials has been employed to 
encapsulate cells or tissues for implantation (Zimmermann et al., 1999). Among those, 
polymers such as alginate, CM-cellulose, κ-carrageenan, and chitosan, which come 
from natural sources, are of particular interest because they are of low cost and 
naturally redeemable. The overwhelming majority of the literature has employed 
sodium alginate for microcapsule formation, due to its excellent biocompatibility and 
biodegradability (Lim and Sun, 1980; Orive et al., 2004; Poncelet et al., 1992).  
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On the other hand, the use of synthetic polymers is limited because of the 
unphysiological conditions that are typically necessary for the encapsulation process 
and/or the potential risks associated with reactive monomers and/or impurities 
(Brodelius and Vandamme, 1987; Lodge and Monaco, 1994; Silver and Doillon, 
1989). Until now, no synthetic polymer has existed that can encapsulate sensitive 
entities under mild conditions (Cohen et al., 1990). 
 
In view of regulatory concerns and safety issues for clinical applications, this higher 
level of safety is a major advantage of natural polymers such as alginates, as compared 
to synthetic polymers (Zimmermann et al., 1999).  
 
2.5.1 Alginate 
Alginate, a naturally occurring biopolymer extracted from brown algae (kelp), has 
several unique properties that have enabled it to be used as a matrix for the entrapment 
and/or delivery of a variety of biological agents (Gombotz and Wee, 1998). Alginate 
polymers are a family of linear unbranched polysaccharides which contain varying 
amounts of 1,4’-linked β-D-mannuronic acid and α-L-guluronic acid residues (Fig. 2.9). 







Figure 2.9 Structure of alginate (MacGregor and Greenwood, 1980) 
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Alginate can be ionically crosslinked by the addition of divalent cations in aqueous 
solution. The relatively mild gelation process has enabled not only proteins, but also 
cells and DNA to be incorporated into alginate matrices with retention of full 
biological activity. Furthermore, by selection of the type of alginate and coating agent, 
the pore size, degradation rate, and ultimately release kinetics can be controlled. 
 
The unique properties of alginate gels include: 
— A relatively inert aqueous environment within the matrix 
— A mild room temperature encapsulation process free of organic solvents  
— A high gel porosity which allows for high diffusion rates of macromolecules 
— The ability to control this porosity with simple coating procedures 
— Dissolution and biodegradation of the system under normal physiological 
conditions 
 
In the past, many researchers have worked on alginate as an ideal delivery system for 
protein antigens. Kwok et al. (1989) reported the potential feasibility of delivering live 
Bacillus Camette Guerin vaccine in alginate microbeads to the lung by either 
inhalation or intravenous injection. Bowersock et al. (1994; 1996) have evaluated the 
use of alginate hydrogels to deliver oral vaccines to different species of animals. Wee 
et al. (1995) showed that strong antibody responses were effectively produced when 
soluble antigens were encapsulated and released from alginate microbeads. And they 
believe that alginate could be successfully used as a mucosal drug delivery vehicle for 





2.4.3 Ca-alginate matrix 
Alginate beads can be prepared by extruding a solution of sodium alginate containing 
the desired protein, as droplets, into a divalent crosslinking solution such as Ca2+, Sr2+, 
or Ba2+. Monovalent cations and Mg2+ ions do not include gelation (Sutherland, 1991) 
while Ba2+ and Sr2+ ions produce stronger alginate gels than Ca2+ (Clark and Ross-
Murphy, 1987). Other divalent cations such as Pb2+, Cu2+, Cd2+, Co2+, Ni2+, Zn2+ and 
Mn2+ will also crosslink alginate gels but their use is limited due to their toxicity 
(Gombotz and Wee, 1998). The gelation and crosslinking of the polymers are mainly 
achieved by the exchange of sodium ions from the guluronic acids with the divalent 
cations, and the stacking of these guluronic groups to form the characteristic egg-box 
structure (Fig. 2.10). Each alginate chain can dimerize to form junctions with many 
other chains and as a result gel networks are formed rather than insoluble precipitates 
(Rees and Welsh, 1977). 
 
  
Figure 2.10 “Egg-box” junction of Ca-alginate matrix (Rees, 1981) 
 
The monomeric composition, block structure, and molecular size of the alginate 
strongly affect the mechanical and swelling properties of the alginate beads (Martinsen 
et al., 1989). Reduction of mechanical properties are observed for alginate with low 
viscosity or molecular weight (Smidsrød, 1990; Johansen and Flink, 1986). The 
stability of alginate beads is quite low in the presence of chelating agents such as 
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phosphate, lactate, and citrate due to shared affinity for calcium, destabilizing the gel. 
Some proposed using ions with better affinity for alginate such as Al3+, Sr2+, and Ba2+ 
to strengthen the gel, but these alternatives may be unacceptable for food applications 
because of potential toxicity. Other ions such as Pb2+ or Cu2+ are more efficient but are 
also more toxic (Dulieu et al., 1999; Gåserød et al., 1999; Groboillot et al., 1994; 
Poncelet et al., 2001). 
 
However, the resulting hydrogel beads are very porous. Polymer coats are often 
applied to ensure better isolation and retention of the encapsulated material. The 
external surface of the beads may also be modified to improve biocompatibility or 
bead strength (Dulieu et al., 1999). Poly-L-lysine and chitosan are the most commonly 
used polycations for capsule production (Gåserød, et al., 1998). My study favours 





Figure 2.11 Structure of chitosan (Chourasia and Jain, 2003) 
 
Chitosan [poly (β-(1→4)-2-amino-2-deoxy-D-glucos)] is a linear polysaccharide 
derived from deacetylated chitin (Fig. 2.11), which is extremely abundant in nature, 
existing widely in mushrooms, yeasts, and hard outer shells of insects and crustaceans 
(Goosen, 1994). Chitosan is soluble in acidic solutions and the positive charge of 
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chitosan interacts strongly with negative surfaces (Kas, 1997). Its properties are listed 
in Table 2.4. 
 
Table 2.4 General properties of chitosan (Kim et al., 1999) 
Chemical Properties Solution Properties Biological Properties 
• Linear polyamine 
(poly-D-glucosamine) 
• Reactive amino groups 
• Available reactive 
hydroxyl groups 
• Chelates many 
transitional metal ions 
• Strong affinity with 
polyanions 
• Soluble at pH<6.5, 
insoluble at pH >6.5 
• Viscous solutions 
• Shear thinning 
• Gel-forming with 
polycations 






    
Chitosan has been evaluated for a variety of therapeutic applications, including 
wound-healing, hemostatic, antimicrobial, osteoconductive, cholesterol-lowering, and 
drug delivery agents. Chitosan has demonstrated physiological compatibility with 
living tissues. It would be difficult to engineer another polysaccharide that could 
surpass chitosan in its variety of functions and applications for therapeutics and 
encapsulation (Kim et al., 1999). 
 
2.5.4 Alginate-chitosan matrix 
Formation of a polyelectrolyte complex has been demonstrated to occur when a 
cationic and an anionic polymer are present simultaneously in aqueous solution. It was 
recognized that the formation of complexes between alginate and chitosan could be 
ascribed to this phenomenon (Murata et al., 1993). Polyanionic beads may be coated 
by polycationic membranes by simply suspending beads in the polycationic solution. 
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This first coating may be followed by a second coating with a polyanionic polymer, 
and so on (Poncelet et al., 2001). The capsules which possessed a multiple membrane 
were much stronger and more flexible than their single-membrane counterparts. 
Consequently, there were fewer ruptured or broken capsules (Goosen, 1996). However, 
it is essential that the outer surface be biocompatible and negatively-charged (Hommel 
et al., 1990; Poncelet et al., 2001). Particularly effective coating materials for the outer 
layer are the highly purified alginates (Dorian and Cochrum, 1997).  
 
The binding of chitosan to an alginate gel can be described as almost irreversible. 
Once the capsules are formed, the exposure to solutions with higher concentrations of 
competing ions (H+ and Na+) have minor influence on the stability of the polyanion-
polycation complex. This high stability is probably caused by cooperative ionic bonds 
between the oppositely charged polymers. The binding between alginate and chitosan 
is considerably stronger than the binding between poly-L-lysine and alginate (Gåserød, 
et al., 1999). McKnight et al. (1988) used chitosan to form a polyelectrolyte complex 
with calcium alginate beads, resulting in durable, strong, and flexible biocompatible 
polymeric membranes around the beads.  
 
Based on this knowledge, Liu et al. (1997) have prepared a new type of porous 
polyelectrolyte complex microspheres from alginate and chitosan, and used it to entrap 
the immune activating growth factor interleukin-2, and also bovine serum albumin-
fluorescein isothiocyanate (FITC-BSA). Polk et al. (1994) tried oral vaccination of 
fish through controlled release of antigens from chitosan-alginate microcapsules. They 
believed the encapsulation technique is a potentially simple, quick and inexpensive 
method of entrapping bioactive materials for vaccine delivery. 
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CHAPTER 3 MATERIALS AND METHODOLOGY 
 
3.1 Materials 
3.1.1 List of chemicals 
Chemicals used in this study are listed below: 
− Acetic acid from Merck (Germany) 
− Alginic acid sodium salt from Sigma (USA) 
− Bovine serum albumin from Sigma (USA) 
− Calcium chloride dihydrate from Merck (Germany) 
− Chitosan (low molecular weight) from Sigma (USA) 
− Partial purified hemagglutinin (HA) protein cultured in Prof. Kwang’s Laboratory  
− Hydrochloric acid from Merck (Germany) 
− Sodium acetate from Merck (Germany) 
− Sodium chloride from Merck (Germany) 
− Sodium citrate from Fluka (Switzerland) 
− Trizma base from Sigma (USA) 
 
Acetic acid is used for preparation of chitosan solution and pH buffer. Sodium alginate 
is used for microcapsule formation. BSA is used for release study. Calcium chloride 
dehydrate is used for microcapsule formation. Chitosan is used as coating material. 
Partial purified HA is the antigen for vaccine delivery. Hydrochloric acid is used for 
pH buffer preparation. Sodium acetate is used for preparation of chitosan solution and 
pH buffer. Sodium chloride is used for saline preparation. Sodium citrate is used for 




3.1.2 Stock preparation 
1. 1 % (w/v) sodium alginate solution 
1) in a beaker introduce 500 ml deionised water 
2) mix gently with a magnetic stirrer 
3) slowly disperse 5 g alginate powder on the liquid surface 
4) leave to stand for two hours to allow alginate grain swelling 
5) mixing strongly for 2 hour 
6) leave to stand overnight to deaerate 
Similar steps can be taken for sodium alginate solution at other concentrations. 
However, it was noted that beyond a 2.0% (w/v) concentration, the high viscosity of 
the solution often caused the equipment involved to fail and made uniform 
microcapsule formation difficult. 
 
For antigen loaded alginate solution, the target proteins (BSA or HA) and alginate 
were dissolved separately in 0.1 M Tris-HCl buffer, pH 7.4, at twice the desired final 
concentration. Equal volumes of the two solutions were mixed giving a final 
concentration. For example, mixing 50 ml 2% (w/v) alginate and 50 ml 1% (w/v) BSA 
resulted in 100 ml 1% (w/v) alginate and 0.5% (w/v) BSA solution. 
 
2. 1 % (w/v) calcium chloride solution  
1) in a beaker introduce 500 ml deionised water 
2) mix gently with a magnetic stirrer 
3) slowly disperse 6.62 g calcium chloride dihydrate powder on the liquid surface 
4) mixing strongly for 30 minutes 
5) leave to stand  for 2 hours to deaerate 
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3. 0.3 % (w/v) chitosan solution 
1) introduce 500 ml 1 % acetic acid solution into a beaker 
2) mix gently with a magnetic hot plate stirrer 
3) slowly disperse 1.5 g chitosan powder on the liquid surface 
4) mixing strongly until dissolution 
5) raise the pH to 6.0 by sodium acetate 
6) leave to stand overnight to deaerate 
 
3.2 Experimental setup 
3.2.1 Equipments and accessories 
Various equipments and accessories used in this study are listed in Fig. 3.1, 
(a) PVC tubing from Cole-Parmer (USA)  
(b) 10 ml and 20 ml plastic syringes from Terumo (Japan); 5 ml plastic syringes from 
Becton & Dickinson (USA)    
(c) 4” × 1” Petri dishes from Iwaki Glass (Japan) 
(d) Needles, 33G from Popper & Sons (USA), others from Becton & Dickinson (USA) 
(e) Single syringe infusion pump from KD Scientific (USA)  
(f) High voltage generator from Spellman HV Electronics (Germany) 
 
3.2.2 System configurations 
The electrostatic extrusion system (Fig. 3.2) consisted of a syringe, storing antigen and 
sodium alginate solution, which was driven by a syringe pump; The solution was fed 
to a needle via PVC tubing; The needle serving as a spray nozzle, was charged by the 
high voltage generator; A Petri dish containing CaCl2 solution was placing on top of 










Figure 3.1 Pictures of equipments and accessories 
 
 
Figure 3.2 System configurations of electrostatic extrusion process 
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3.3 Experimental procedures 
3.3.1 Microcapsule formation 
The microcapsules containing active antigens were formed by the following steps: 
1) The antigens were suspended uniformly in sodium alginate solution in Tris-HCl 
buffer or other buffers. 
2) Introduced about 10 mL of the solution to a 10-mL plastic syringe, connected 
the syringe with the needle via PVC tubing, put back the plunger, and attached 
the syringe to the syringe pump. 
3) Introduced 50 ml of 1% calcium chloride into a Petri dish. Positioned the 
supporting stand so that the needle tip was about 1-4 cm from the surface of the 
CaCl2 collection solution. To avoid surface aggregates, the surface tension of 
the CaCl2 solution was lowered with addition of 5% (v/v) of ethanol. 
4) Mixed the collection solution with a magnetic stirrer at low speed. 
5) Attached the positive electrode wire to the stainless steel needle and the ground 
wire to the collection solution. 
6) Switched on the syringe pump and waited for the first few drops to come out of 
the end of the needle. After the first drop or two has been produced, switched on 
the voltage power supply. Desired voltage values were preset. 
7) Needle oscillation might be observed as voltage rose to its critical value. This 
needle vibration would produce a bimodal microcapsule size distribution. 
8) Left the microcapsules to stand for 30 min to ensure full gelation. 
9) The microcapsules were centrifuged using an Allegra X-12R centrifuge 
(Beckman Coulter, UK) at 1000 rpm for 5 min and the supernatant decanted. 
10) For chitosan coating, an outer layer was formed by dipping the microcapsules 
into 30 mL of a 0.3% (w/v) chitosan solution for 2-10 minutes. Then, those 
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microcapsules were centrifuged at 1000 rpm for 5 min and the supernatant 
decanted. After that, microcapsules were washed with 30 mL each of 0.1 M 
Tris-HCl buffer and 1.0% CaCl2 solution. 
11) Finally, the microcapsules were stored in Tris-HCl buffer or other mediums for 
release study. 
 
3.3.2 Antigen release  
3.3.2.1 Release medium preparation 
All mediums used in this study are 0.1 M Tris-HCl buffer pH 7.4 or otherwise stated. 
Proper pH buffers were prepared and used as release medium for antigen release study.  
1. 0.1 M Tris-HCl buffer pH 9 
1) Stock solution A: 0.2 M solution of tris(hydroxymethyl)aminomethane (24.2 
g Trizma base in 1000 ml of distilled water) 
2) Stock solution B: 0.2 M HCl (17.24 ml concentrated HCl dilute to 1000 ml 
with distilled water) 
3) Mixing 50 ml of A and 5.0 ml of B and diluted to a total of 100 ml with 
distilled water 
 
2. 0.1 M Tris-HCl buffer pH 7.4 
1) Stock solution A: 0.2 M solution of tris(hydroxymethyl)aminomethane (24.2 
g Trizma base in 1000 ml of distilled water) 
2) Stock solution B: 0.2 M HCl (17.24 ml concentrated HCl dilute to 1000 ml 
with distilled water) 




3. Sodium acetate buffer pH 5.0 
1) Stock solution A: 0.2 M acetic acid (11.5 ml glacial acetic acid dilute to 1000 
ml with distilled water) 
2) Stock solution B: 0.2 M solution of sodium acetate (27.2 g sodium acetate 
trihydrate or 16.4 g sodium acetate anhydrate in 1000 ml of distilled water) 




Dissolving 9 g sodium chloride in 1000 ml of distilled water 
 
3.3.2.2 BSA release 
1) Microcapsules, generated from 4 ml alginate-BSA (1% w/v alginate, 0.5% w/v 
BSA) solution, were added to 100 ml of release medium in 100 ml conical flask.  
2) The flasks were then placed on a Forma Orbital Shaker (Thermo Electron Co., 
USA) at room temperature and stirred at 200 rpm.  
3) At each sampling period, 3 ml of release medium was removed and replaced 
with fresh medium.  
4) The removed sample was analyzed for BSA concentration via UV absorption at 
280 nm; all tests were done in triplicate. 
 
3.3.2.3 HA release 
1) Microcapsules, generated from 2 ml alginate-HA (1% w/v alginate, 0.075% w/v 
partial purified HA) solution, were added with 1 ml of Tris-HCl buffer solution 
in 2 ml microtubes.  
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2) The microtubes were then placed on a shaker at room temperature and stirred at 
200 rpm.  
3) At each sampling period, the microtubes were centrifuged using a Denville 2600 
microcentrifuge (Denville Scientific, USA) at 10,000 rpm for 4 min; all 
supernatant was removed and replaced with fresh medium.  
4) The removed samples were analyzed by a BCA protein assay kit (Pierce, USA) 
and SDS-PAGE/Western blotting method (see appendices); all tests were done 
in triplicate. 
 
3.4 Determination of microcapsule properties 
3.4.1 Particle size 
Microcapsule size was determined by laser diffraction using Coulter LS 230 Particle 
Size Analyzer (Beckman Coulter, UK). Microcapsule samples, generated from 
approximately 10ml of alginate solution, were dispersed in 1.0% (w/v) CaCl2 solution.  
This suspension solution was used instead of de-ionized water to minimize the 
swelling of the microcapsules during the size analysis process. The suspension was 
then added to the sample chamber of a Coulter LS 230 under moderate stirring. 
Particle size distribution was then determined as a function of the particle diffraction 
using the Coulter software, and plotted as a function of volume percentage. All tests 
were done in triplicate. 
 
To estimate the droplet size by scaling laws, the electrical conductivity of the sodium 
solution was measured by Oakton Conductivity meter (Eutech, Singapore). The 




3.4.2 Microcapsule morphology 
Scanning electron microscopy (SEM) (JEOL, JSM-5600V, Japan) was used to 
determine microcapsule morphology. Microcapsules, after freeze-dried, were mounted 
on aluminium SEM stubs using double-sided NEM tape (Nisshin EM, Japan). The 
samples were sputter coated with platinum for 40 seconds under a vacuum 
environment with an auto fine coater (JEOL, JFC-1300, Japan). Coated samples were 
examined with SEM operating at an accelerating voltage of 15 kV.  
 
In addition to SEM, a fluorescence microscope (Leica DMLM, Germany) and an 
optical microscope (Olympus ULBD-2, Japan) were used to determine the 
morphology.  In this way, the microcapsules need not go through freeze drying, and 
they were able to retain their original shape for morphology study. 
 
3.4.3 BSA release 
For BSA release study, a 3 ml sample of each solution was removed periodically for 
analysis, and 3 ml medium was added after each removal to maintain a constant 
volume. The absorbance of each solution collected was determined 
spectrophotometrically at 280 nm using a UV-VIS spectrophotometer (UV Mini 1240, 
Shimadzu, Japan). 
 
Meanwhile, total concentration of BSA in the microcapsules was determined after the 
microcapsules were dissolved completely in sodium citrate (10% w/v) solution. And 
the amount of BSA lost to the external collecting solution during the extrusion process 
was also analyzed by UV spectrophotometer as described above. The encapsulation 
efficiency was calculated as the ratio of the actual and the theoretical BSA content. 
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3.4.4 HA release 
HA concentrations in the samples were measured by BCA Protein Assay Kit (Pierce, 
USA) and SDS-PAGE/Western blotting methods (Gallagher and Smith, 2005a; 
Gallagher et al., 2005b; Sasse and Gallagher, 2005).  
 
Basically, BCA protein assay combines the well-known reduction of Cu+2 to Cu+1 by 
protein in an alkaline medium (the biuret reaction) with highly sensitive and selective 
colorimetric detection of the cuprous cation (Cu+1) using a unique reagent containing 
bicinchoninic acid (BCA). The purple-coloured reaction product of this assay is 
formed by the chelation of two molecules of BCA with one cuprous ion. This water-
soluble complex exhibits a strong absorbance at 562 nm that is nearly linear with 
increasing protein concentration. Accordingly, protein concentrations could be 
determined and reported with reference to standards of a common protein such as BSA. 
 
Since proteins with different molecular weight would have different size, we could 
also use sodium dodecyl sulfate (SDS) to denature all proteins to the same linear shape, 
followed by polyacrylamide gel electrophoresis (PAGE). In this way, proteins were 
separated according to their size. Proteins separated by SDS-PAGE could be detected 
using Coomassie blue. After destaining, the blue protein bands appear against a clear 
background. The protein located around 35 kDa marks was believed to be HA protein. 
It could be further confirmed by Western blotting method, which allowed researchers 





CHAPTER 4 RESULTS AND DISCUSSION 
 
4.1 Optimum conditions for antigen encapsulation 
The size of the microcapsules formed is absolutely crucial to the successful 
implementation of this technology. As mentioned earlier, the microcapsules were 
analyzed using the particle size analyzer to determine its mean size. A typical result 
obtained from the particle size analyzer is shown in Fig. 4.1. Notably, satellite peaks 




















Figure 4.1 A typical result from the particle size analyzer 
 
Satellites are formed by breakage of the fine filament between the droplet and the 





Figure 4.2 Satellite formation under an electrical potential (Speranza et al., 2001) 
 
In the following sections, several factors governing the electrostatic extrusion process 
will be discussed, namely, applied voltage, pump flow rate, electrode spacing, and 
needle size. Experiments were designed to determine the optimum conditions for 
production of smaller microcapsules. A set of standard conditions is listed in Table 4.1. 
 
Table 4.1 Control parameters for microencapsulation experiments 
Control Parameters Set Values Units 
Applied Voltage 8.0 kV 
Syringe Pump Flow Rate 5.0 ml/h 
Electrode Spacing 2.0 cm 
Needle Size 30 G 
Sodium Alginate Concentration 1.0 % w/v 
Calcium Chloride Concentration 1.0 % w/v 
 
The set values would be replaced if it did not match the optimum condition for 
microcapsules production, for example, if smaller microcapsules formed at 7 kV, then 





4.1.1 Effect of applied voltage 
Table 4.2 and Figure 4.3 showed the experimental conditions and results of changes in 
applied voltage on the microcapsule sizes. 
 
Table 4.2 Effect of applied voltage on microcapsule formation 
Control Parameters 
y Syringe Pump Flow Rate — 5.0 ml/h 
y Electrode Spacing — 2.0 cm 
y Needle Size — 30 G 
y Na-Alginate Concentration — 1.0% w/v 
y Calcium Chloride Concentration — 1.0% w/v 
 
Variable Parameter & Results 
Applied 
Voltage (kV) 0 1 2 3 4 5 6 7 8 10 
Microcapsule 
sizes (μm) 1383 1314 1105 1025 603 160 146 92.4 109 177 
Coefficient of 




























































(c) Microcapsule size vs. size distribution 
Figure 4.3 Effect of applied voltage on microcapsule formation 
 
As shown by Fig. 4.3 (a), it was clear that as electric potential increases, the size of the 
microcapsule decreased dramatically. However, as applied voltage was raised above a 
critical value, there was no significant further decrease in microcapsule diameter. As a 
result, the solution would exit the needle as a jet, and the size of the capsules was 
mainly determined by the jet instability rather than the applied voltage. Another 
interesting finding was, as electric potential increases, the size distribution of the 
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microcapsules increased as well (Fig. 4.3 b). By plotting the size distribution as a 
function of microcapsule size; the size distribution increased when the microcapsule 
size decreased (Fig. 4.3 c). In my study, it was not possible to obtain small 
microcapsules with a narrow size distribution.  
 
As far as size distribution is concern, the rising trend was primarily caused by the 
change of dispersion mode, e.g., from dripping mode to cone-jet mode, under 
electrical field. Without electric field, the droplets were detached from the tip of the 
needle separately (Fig. 4.4 a). The droplet was gradually drawn into a cone by the 
electric field (Fig. 4.4 b), and as the droplet falls, a fluid filament connects the droplet 
to the next forming droplet. Beyond a critical applied voltage, droplets no longer 
formed; instead the solution poured from the needle in a steady stream (Fig. 4.4 c).  
 
 
(a) V = 0 kV  (b) V = 4 kV  (c) V = 6 kV 
Figure 4.4 Transition from dripping mode to cone-jet mode (by digital camera) 
 
As shown in Fig. 4.2, just prior to release from the needle, the droplets remain 
attached by a small liquid column. Turbulence or a vibration of even very small 
intensity was able to break this liquid cylinder. This secondary breakage leads to small 
droplet satellites. Sample and Bollini (1972) stated that, satellite formation usually 
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accompanies with higher applied voltages, since under these conditions the elongation 
of the liquid neck prior to rupture is much more pronounced.  
 
Meanwhile, as the voltage was increased above its critical value, a high surface charge 
and an electric field on the surface of capillary tip gave rise to a mechanical force 
causing needle vibration and resulting in an oscillating thread-like filament. The 
greatest deduction in microcapsule size was observed when natural needle oscillation 
was observed, that means, oscillation in other frequencies will form larger 
microcapsules. Therefore, the smallest micropcapsules were observed at 7 kV of 
applied voltage in my experiment, which was also corresponding to a relatively 
narrow size distribution. As the applied voltage increased further to 10 kV, kink 
instability occurred, causing an unstable jet to be emitted from the needle, resulted in a 







(a) V = 7 kV    (b) V = 10 kV 
Figure 4.5 Stable and unstable jet emission from the needle 
 
Following the work done by Poncelet et al. (1999b), the microcapsules size may be 







−≅ lnln . The numerical 
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estimation of the critical electrical potential by equation (2.6) or ooccr kdU εγ /=  
gives the value Ucr = 1.6 kV, for γo = 0.072 N/m, dc = 0.3 mm, εo = 8.85 x 10-12 F/m 
and k = 1. This value is significantly different from the experimentally observed value 
of Ucr ranging from 4 kV to 5 kV. Therefore, an appropriate fitting parameter k must 
be assigned for valid estimation of Ucr value. Meanwhile, Poncelet et al. (1993), 
proposed another equation for estimation of Ucr: 
2.0
cr h419.9U =         (4.1) 
Where, h is the distance between the droplet and collecting solution.  
The estimation of the critical electrical potential by this equation gives the value Ucr = 




















My data Poncelet's model
Linear (My data) Linear (Poncelet's model)
 
Figure 4.6 Linear models for microcapsule size estimation 
 
Comparing Poncelet’s model, where 3121 /])/([)( cro UUdUd −≅ , with my 
experimental data (Fig. 4.6), I found that my data also supported a good linear model 
for microcapsule size estimation, but with differences in exponential coefficient. It 
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might due to the effect of droplet shrinkage during microcapsules formation. 
Therefore, the sizes measured after microcapsule formation would be different from 
the sizes of the droplets emitted from the needle.  
 
4.1.2 Effect of flow rate 
The tests for flow rate were carried out at 7 kV, which was found to be the optimum 
electric potential for my experiment. Table 4.3 and Figure 4.7 showed the 
experimental conditions and results of changes in flow rate on the microcapsules sizes. 
 
Table 4.3 Effect of flow rate on microcapsule formation 
Control Parameters 
y Applied Voltage — 7.0 kV 
y Electrode Spacing — 2.0 cm 
y Needle Size — 30 G 
y Na-Alginate Concentration — 1.0% w/v 
y Calcium Chloride Concentration — 1.0% w/v 
 
Variable Parameter & Results 
Flow rate 
(ml/hr) 2 3 5 7 8 10 
Microcapsule 
sizes (μm) 68.2 80.5 92.4 120.4 142.7 150.9 
Coefficient of 












































(b) Flow rate vs. size distribution 
Figure 4.7 Effect of flow rate on microcapsule formation 
 
When the pump flow rate was slower, a less volume of solution was assembled at the 
needle tip at the time of droplet detachment, and smaller droplets could be expected. 
Another explanation was, lower flow rate would give more time for counter ions, e.g., 
Na+, to diffuse to droplet surface under positive electric potential and reduce the 
surface tension, and thus smaller microcapsules could be generated. It was confirmed 
by my experimental data (Fig. 4.7 a). However, though a slower flow rate would 
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generate smaller microcapsules, the production capacity also dropped significantly. On 
the other hand, as flow rate rose above 10 ml/h, the syringe pump could no longer 
work properly, i.e., the flow rate became inconsistent, and this limited the production 
capacity for my system.  
 
Microcapsule size distribution also increased steadily with increasing flow rate (Fig. 
4.7 b). With increasing flow rate, more alginate solution was passing through the 
needle per time, resulted in larger microcapsules and surface tension. According to 
Poncelet et al. (1993), the greater the force required to break the droplet, the higher 
would be the resultant size dispersion, so were my results. After balancing the trade-
off among beads size, size distribution, and production capacity, the optimum 
condition for syringe pump flow rate was set to be 5 ml/h.  
 
Meanwhile, I also examined the scaling laws developed by Gañán-Calvo et al. (1997), 
which established a relationship between droplet size and volumetric flow rate, in my 
study.  
 
Table 4.4 Physical properties of 1% Na-alginate solution 













1002 0.0732 0.123 0.2024 8.85 x 10-12
 
Using the liquid properties listed in Table 4.4, the dimensionless viscous parameter δμ, 
calculated by equation (2.18), has a value of 0.002495 for the 1% (w/v) sodium 
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alginate solution. Since δμ < 1, then I have d ∝ jv1/3 or d = k jv1/3. My data showed a 



























Figure 4.8 Scaling laws for 1% Na-alginate solution 
 
Therefore, the scaling laws need to be modified to a more general form to provide 
better droplet size estimation in my case. According to Gañán-Calvo et al (1997), if 
charge is advected with a velocity of the order of the bulk velocity jv/d2 (highly 
viscous and conducting liquids) one has d ~ jv1/3; on the other hand if charge is 
advected with a larger velocity, almost independent of jv (liquid with sufficiently low 
viscosity and conductivity) then d ~ jv1/2. Therefore, I proposed the following modified 
scaling laws: 
d ∝ jvn          (4.2) 
n
vj'kd =          (4.3) 



















Figure 4.9 Modified scaling laws for 1% Na-alginate solution 
 
As shown in Fig. 4.9, a much better corresponding relationship between flow rate and 
microcapsule size was presented by the modified scaling laws. In the experiment, the 
results show n ≈ ½, which means the viscosity or the surface tension of the solution 
has been reduced significantly under the electrostatic force. 
 
4.1.3 Effect of electrode spacing 
The electrode spacing was defined as the distance between the tip of the needle and 
the surface of the collecting solution. Table 4.5 and Figure 4.10 showed the 









Table 4.5 Effect of electrode spacing on microcapsule formation 
Control Parameters 
y Applied Voltage — 7 kV 
y Syringe Pump Flow Rate — 5.0 ml/h 
y Needle Size — 30 G 
y Na-Alginate Concentration — 1.0% w/v 
y Calcium Chloride Concentration — 1.0% w/v 
 
Variable Parameter & Results 
Electrode 
Spacing (cm) 1 1.5 2 2.5 3 4 
Microcapsule 
sizes (μm) 95.4 88.0 92.4 119.3 130.0 147.8 
Coefficient of 













































(b) Electrode spacing vs. size distribution 
Figure 4.10 Effect of electrode spacing on microcapsule formation 
 
In the study of electrostatic extrusion, I understand that electrostatic force Fe depends 
on the geometric parameters of the experimental dropping set-ups. For my system, the 
electrostatic force Fe can be expressed by equation (2.4) or  
Fe ∝ (1/h)2         (4.5) 
Where, h is the distance between the droplet and collecting solution. 
Therefore, a reduction in the electrode spacing would increase the electrical force and 
intensity of the electric field between the needle and the solution. According to 
equation (2.3), any increase in Fe would help counteract the surface tension, and 
produce smaller droplets. Hence, microcapsule sizes would decrease as the electrode 
spacing decreases (Fig. 4.10 a). 
  
However, the size distribution of microcapsules increased with the electrode spacing 
(Fig. 4.10 b). One possible explanation for this phenomenon was, when the various 
droplets penetrate the collecting solution, they might break again, giving rise to even 
smaller droplets and/ or satellites. The larger distances between the needle tip and the 
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collecting solution, the more likely the droplet would break into satellites when it 
reached solution surface, hence increased the size distribution. 
 
The optimum distance was found to be 1.5 cm, below this value, sparks might be 
produced across the electrical fields due to ionization of the air. It induced system 
instability, resulted in relatively larger microcapsule size and wider size distribution at 
1 cm electrode spacing, as shown in Fig. 4.10. 
 
4.1.4 Effect of needle size 
Needles range from 22 Gauge to 33 Gauge were used in this study, however, 33 G 
needle was highly prone to clogging, and the flow was extremely unstable. Therefore, 
results from 33 G needle were excluded in this discussion. Table 4.6 and Figure 4.11 
showed the experimental conditions and results of changes in needle size on the 
microcapsule sizes. 
 
Table 4.6 Effect of needle size on microcapsule formation 
Control Parameters 
y Applied Voltage — 7 kV 
y Syringe Pump Flow Rate — 5.0 ml/h 
y Electrode Spacing — 1.5 cm 
y Na-Alginate Concentration — 1.0% w/v 
y Calcium Chloride Concentration — 1.0% w/v 
 
Variable Parameter & Results 
Gauge 23 25 26 27 30 Needle 
Size O.D. (mm) 0.64 0.51 0.46 0.41 0.30 
Microcapsule sizes (μm) 411.9 203.3 186.0 120.2 88.0 
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(b) Needle size vs. size distribution 
Figure 4.11 Effect of needle size on microcapsule formation 
 
According to Tate’s law, surface tension of the droplet is proportional to the diameter 
of the pendant droplet neck, which is approximately equal to outer diameter of the 
needle. Therefore, from equation (2.1) and (2.2), I can see a larger do with a larger 
needle; and from equation (2.6), I can see a larger Ucr value for a larger needle. By 
combining these two factors in equation (2.9), I can expect a rise in microcapsule size 
by increasing the needle size, as shown in Fig. 4.11 (a). In practice, with a smaller 
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orifice, the base area of the Taylor cone was reduced, forcing a sharper apex to be 
formed at the same flow rate since the volume of liquid expelled remains unchanged. 
This gave rise to a lower jet diameter and consequently, smaller droplets upon jet 
collapse. 
 
According to Poncelet et al. (1993), any perturbations in electric field or vibration 
during droplet generation will lead to variation in droplet diameter and formation of 
satellite droplets. These perturbations act more on small drops or jets, and the small 
jets are themselves more easily broken than the larger jets. Their opinion was clear 
reflected in my results, as show in Fig. 4.11 (b). 
 
Overall, the optimum conditions for microcapsules formation in my experimental set 
up were: 7 kV for applied voltage, 5 ml/h for syringe pump flow rate, 1.5 cm electrode 
spacing and 30 G needle.  
 
I also understood that, narrowing the size distribution in the electrostatic extrusion 
process required a careful design of the system configurations. The needle must be 
precisely centered to avoid any source of vibration. The distance between the needle 
tip and the collecting solution must be carefully adjusted. The flow rate driven by the 
syringe pump must be reliable and consistent. 
 
4.2 Microcapsule morphology 
Ca-alginate matrix is very porous, as shown in Fig. 4.12, results in a quick release of 





(a) SEM picture of Ca-alginate microcapsule surface 
 
(b) Optical microscope picture of Ca-alginate microcapsule surface 
 
(c) Fluorescence microscope picture of Ca-alginate microcapsule surface 
Figure 4.12 Ca-alginate microcapsule surface 
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Gombotz and Wee (1998) suggested that, the porosity of an alginate gel can be 
significantly reduced by partially drying the microcapsules. Complete dehydration of 
alginate beads, however, can result in surface cracking which can facilitate the surface 
erosion of the beads upon rehydration. Batich and Vaghefi (2000) even warned that, 
any drying distorted the shape and size of the capsules and resulted in a shrunken mass 
of solid material. Even lyophilization and critical point drying caused distortion. 
Therefore this approach is not considered in this study. 
 
4.2.1 Effect of pH on microcapsule surface 
A reduction in pore size of an alginate matrix may also be achieved by exposing the 
microcapsules to lower pH. Ca-alginate microcapsules formed at different pH will 
have different surface structure, as shown in Fig. 4.13 (under optical microscope).  
         
(a) pH = 5   (b) pH = 7.4  (c) pH = 9 
Figure 4.13 pH effects on microcapsule surface structure 
 
It was shown that at pH 5, a layered structure matrix was observed. And those formed 
at pH 9 were shown to be more porous than at pH 7.4, which would result in a faster 
release of the beads at higher pH values. This different surface structure would affect 
the BSA release from the alginate matrix latterly. A possible explanation for it may be 
the lower the pH, the higher the [H+]. As Ca-alginate microcapsule is negatively 
charged, the H+ will help neutralizing the negative charge and coating a hydrous layer 
on the microcapsule surface, hence make it smoother. 
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4.2.2 Effect of chitosan coating on microcapsules surface 
The surface porosity of microcapsule will be reduced significantly by polymer coating, 
which ensures better isolation and retention of the encapsulated material. In my case, 
the ca-alginate microcapsules were coated with 0.3% chitosan solution. The results 
were shown in Fig. 4.14. The additional layer of chitosan coating on the calcium 
alginate microcapsules can be clearly seen in the optical microscope after coating in 
chitosan for 2 minutes (Fig. 4.14 b).  
 
   
  No coating    With chitosan coating 
(a) Fluorescence microscope pictures of Ca-alginate microcapsule surface 
   
No coating    With chitosan coating  
(b) Optical microscope picture of Ca-alginate microcapsule surface layer 
Figure 4.14 Ca-alginate microcapsule surface (No coating Vs. Coating) 
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Prolonging the coating time resulted in the formation of thicker and more compact 
membranes due to the greater number of ionic bonds established between chitosan and 
the alginate core. This could be seen in the SEM pictures in Figure 4.15. The surface 
was observed to be much more compact after coating with chitosan for 10 minutes.   
 
    
(a) No chitosan coating   (b) 2 minutes chitosan coating 
    
(c) 4 minutes chitosan coating  (d) 10 minutes chitosan coating 
Figure 4.15 SEM pictures of microcapsules with different coatings 
 
Similar results were also presented by Taqieddin and Amiji (2004), the calcium 
alginate chitosan beads in the Fig. 4.16 can be seen as having a highly porous core, 
resulting from freeze-drying of liquid alginate, and a uniform chitosan layer, that 




Figure 4.16 SEM picture of freeze-dried Ca-alginate–chitosan microcapsule 
(Taqieddin and Amiji, 2004) 
 
4.3 Antigen release 
Antigens entrapped in alginate matrices are released by two mechanisms: i) diffusion 
of the proteins through the pores of the polymer network, and ii) degradation of the 
polymer network. Analysis of Ca-alginate microcapsules by microscopy has shown 
that the pore size ranges from 5 nm to 200 nm in diameter (Fig. 4.12). There is a more 
constricted polymer network on the microcapsule surface than in the microcapsule 
core (Fig.4.16).  
 
Table 4.7 lists several factors that may be exploited to control membrane permeability 
in microencapsulation systems. In my study, effects of differences in size, pH, 
loadings, chitosan coating time and release mediums were studied for BSA release 






Table 4.7 Factors in the control of microcapsule permeability (Goosen, 1994) 
• Polymer molecular weight 
• Physical integrity 
• Thickness 
• Chemical structure 
Capsule Wall 
• Multiple membranes 
Process Factors 
• Membrane polymer concentration 











• Electrical charge 
 
4.3.1 BSA release from alginate matrices 
A typical release profile for BSA is shown in Fig. 4.17. Initially, a burst of BSA was 
observed due to release of BSA located near the microsphere surface. This was 
followed by a period of slow release which was attributed to degradation of the 
microsphere and diffusion of the drug out of the microsphere. The third phase was 
described as a secondary burst of BSA, and was attributed to the increased 





















Figure 4.17 The release of BSA from alginate matrix (Parameters: Size 0.15 mm; 
0.5% BSA loading; No coating & Tris-HCl buffer with pH 7.4) 
 
4.3.1.1 Effect of microcapsule size  
The effect of microcapsule size on the release profiles of BSA is shown in Fig. 4.18. 



















0.15 mm 0.7 mm 1.6 mm
 
Figure 4.18 Effect of microcapsule size on BSA release 
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The microcapsules with mean particle size of 150 μm exhibited an initial release of 
about 40% of BSA loaded within the first day, comparing to about 25% for 700 μm 
microcapsules and about 25% for 1600 μm microcapsules. This was attributed to the 
small microcapsule size and resultant increase in surface area. And mass transfer is 
directly proportional to the surface area of the spherical microcapsules.  
 
4.3.1.2 Effect of pH 
As the alginate gel network is negatively charged, the pH will also influence the 
diffusion of charged substrates and products. The release profiles of the BSA from Ca-



















pH 5 pH 7.4 pH 9
 
Figure 4.19 Effect of pH on BSA release 
 
As shown in Fig. 4.19, the rate of release of BSA from alginate microcapsules 
increases with increasing pH as a result of the increased negative charges on the 
protein and increased pore size (Fig. 4.13). After 24 h, only 25% of the entrapped BSA 
was released from the capsules at pH 5.0, compared with 40% release at pH 7.4 and 
55% release at pH 9.0. 
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A protein with overall net positive charge can potentially interact with the negatively 
charged alginate polymer, thus inhibiting diffusion from the gel. And according to 
Gombotz and Wee (1998), acidic proteins are less likely to interact with the anionic 
alginate polymer; while basic proteins interact with the alginate polymer network and 
hence diffusion through the pores is greatly hindered. BSA has an isoelectric point of 
4.90, and belongs to acidic proteins. It will be negatively charged at pH 7.4 and 9, and 
almost neutral at pH 5. However, an attempt to entrap BSA at pH 4 failed, as 
precipitation occurred while preparing BSA-alginate solutions. 
 
4.3.1.3 Effect of BSA loading 
Different loadings of BSA would result in different BSA release patterns from the 























0.75% BSA 0.5% BSA 0.25% BSA
 
Figure 4.20 Effect of BSA loading on BSA release 
 
Generally, a higher initial loading of BSA would result in a faster release from the 
microcapsules, due to higher driving force for diffusion from the microcapsules. For 
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instance, most BSA was released out from the microcapsules during the first 2 weeks 
at a 0.75% w/v BSA loading. 
 
4.3.1.4 Effect of chitosan coating 


















No coating 2 min coating 10 min coating
 
Figure 4.21 Effect of coating time of chitosan on BSA release 
 
As shown in Fig. 4.21, the release of BSA decreased when coating time increased. 
With coating period longer than 10 min, the mass transfer was seriously hindered. This 
was attributed to the additional chitosan layer formed around the Ca-alginate 
microcapsules. With chitosan coating, surface of the microcapsules became much less 
porous and thus reduced the rate of diffusion significantly. 
 
When Ca-alginate microcapsules were suspending in the chitosan solution, the 
formation of polyelectrolyte complexes between alginate and chitosan occurred. With 
short coating time, it might not give the sufficient interaction time for the chitosan-
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alginate matrix. Therefore, the Ca-alginate microcapsules coated for 2 minutes showed 
faster release behavior that those coated for 10 minutes.  
 
4.3.1.5 Effect of release environment 


















Tris-HCl Buffer (pH 7.4) Saline
Tris-HCl Buffer (No shaking) Saline (Total replacement)
 
Figure 4.22 Effect of release medium on BSA release 
 
A significant drop in release rate was observed if I do not shake the release medium. 
Without shaking, there would be an accumulation of boundary layer around the 
microcapsules, which would delay the release of BSA from the microcapsules. 
 
The release of BSA in saline solution was slower than in Tris-HCl buffer, because 
saline solution has a pH around 5.5, resulting from ionic strength effect and 
dissolution of CO2 from the air. Hence, it followed the pattern of pH effect on BSA 
release. However, if I replaced the entire saline medium during sampling, a much 
faster release of BSA from the microcapsules would be observed, because the excess 
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Na+ would accelerate the erosion of Ca-alginate microcapsules. If fact, all the 
microcapsules were dissolved within one week. 
 


























0.15 mm / pH 5 / 0.25% BSA / No coating / Tris-HCl buffer (pH 7.4)
0.7 mm / pH 7.4 / 0.5% BSA / 2 min coating / Saline
1.6 mm / pH 9 / 0.75% BSA / 10 min coating /
Figure 4.23 BSA encapsulation efficiency and release conditions 
 
Figure 4.23 showed the relationship between BSA encapsulation efficiency and the 
different release conditions.  
— Effect of size: the encapsulation efficiency increased with increase of 
microcapsule size, it was assumed that the BSA lost to CaCl2 solution during the 
microcapsule formation was directly proportional to the specific surface area of the 
microcapsules, i.e., large microcapsules lost less BSA to the collecting solution.  
— Effect of pH: pH has limited effect on encapsulation efficiency; however, the 
efficiency has a relatively higher value at pH 5 than others. BSA has an isoelectric 
point of 4.90, so it’s almost neutral at pH 5, hence it’s less repulsive with the 
negatively charged alginate polymer comparing to higher pH values, thus 
inhibiting diffusion from the microcapsules. Therefore, less BSA will be lost 
 75
Chapter 4 
during encapsulation at pH 5. Meanwhile, pH 5 buffer (sodium acetate) consists of 
Na+, which would accelerate the exchange between Na+ and Ca2+, hence 
stimulated the crosslinking and formation of microcapsule wall, which eventually 
reduced the loss of BSA from the microcapsules.  
— Effect of BSA loading: With a higher BSA loading, more BSA would be present 
in the CaCl2 solution during ionic crosslinking, which could prohibit diffusion of 
BSA from microcapsules, and reduce the loss. Therefore, microcapsules generate 
with 0.75% BSA loading have the highest encapsulation efficiency at about 27%. 
— Effect of chitosan coating: as coating occurred after the formation of Ca-alginate 
microcapsules, some BSA would be certainly lost during the coating process, 
therefore the encapsulation efficiency would decrease as coating time increased. 
— Effect of release medium: same as sodium acetate buffer, saline consists of Na+, 
which would accelerate the formation of microcapsule wall, and hence reduced the 
loss of BSA from the microcapsules. Therefore, encapsulation efficiency was 
higher in saline medium compared to Tris-HCl buffer. 
 
4.3.2 HA release from alginate matrices 
Slightly truncated HA proteins were firstly generated by the baculovirus expression 
system, in which insect cells (Spodoptera frugiperda clone 9 or Sf-9 cells) were 
infected with recombinant baculovirus encoded HA genes. These Sf-9 cells were later 
suspended in lysis buffer, lysed using ultrasonication. The partially purified HA 
proteins were finally obtained after centrifugation. 
 
In vitro release pattern of HA protein in Tris-HCl buffer (0.1M, pH 7.4), which was 
generated in terms of the cumulative release (%) versus time, was shown in Fig. 4.24. 
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The total amount of partial purified HA proteins encapsulated was calculated to be 
0.22 mg. An initial burst over the first three days was observed. About 20% proteins 
were released within the first 24 h. And only 70% of proteins were released from Ca-






















Figure 4.24 HA release from alginate matrix in Tris-HCl buffer 
 
After chitosan coating, the release rate was much slower, and similar patterns were 
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Figure 4.25 Effect of chitosan coating on HA release 
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SDS-PAGE was also performed to investigate the release pattern of HA (Fig. 4.26). 
The bands fainted as time went on, indicating the descending of HA release rate. And 
the identity of HA was further confirmed by Western blotting, as shown in Fig. 4.27. 
 
























Figure 4.26 SDS-PAGE results of HA release (lane 1, protein marker; lane 2, HA 
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Figure 4.27 Western blotting results of HA release (lane 1, protein marker; lane 2, 




CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Conclusions 
Electrostatic extrusion is a novel extrusion technique that uses electrostatic forces to 
form a charged stream of small droplets. Alginate, a naturally polysaccharide, can be 
ionically crosslinked by the addition of divalent cations in aqueous solution. The 
combination of these two aspects has enabled me to develop a technique for the 
entrapment and/or delivery of antigen in control of pathogen. 
 
I found that applied voltage, flow rate, electrode spacing and needle size played theirs 
roles in microcapsules formation. As applied voltage increased until a critical value, 
the size of the microcapsules decreased dramatically, but the size distribution of the 
microcapsules increased. As a result, it was not possible to obtain small microcapsules 
with a narrow size distribution in present conditions. A modified linear relationship 
was observed between microcapsules size and applied voltage based on Poncelet’s 
model. Above the critical value, there was no significant decrease in microcapsule 
diameter by higher voltage. Further reduction in microcapsule size was achieved by 
reducing flow rate, which would give more time for counter ions to diffuse to droplet 
surface and minimize the surface tension. I also modified the scaling laws, developed 
by Gañán-Calvo and fellows, to show a better corresponding relationship between 
flow rate and microcapsule size in my study. 
 
As expected, microcapsule sizes decreased as the electrode spacing decreased, due to  
increase in electrical force and intensity of the electric field between the needle and 
the solution. And smaller needles produced smaller microcapsules. The overall 
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optimum conditions for microcapsule production with 1% w/v Na-alginate and 1% 
w/v CaCl2 were: 7 kV for applied voltage, 5 ml/h for syringe pump flow rate, 1.5 cm 
electrode spacing and 30 G needle. 
 
Pictures taken by SEM and other microscopes showed that, Ca-alginate matrix has 
very porous surface structure. A reduction in pore size of an alginate matrix was 
observed by exposing the microcapsules to lower pH. The surface porosity was clearly 
reduced by applying chitosan coating. The additional layer of chitosan coating on the 
calcium alginate microcapsules was confirmed by observation under microscopes. 
 
In vitro results showed protein release was affected by microcapsule size, pH, protein 
loading, and release medium. A faster protein release was observed for smaller 
microcapsules, at higher pH, with higher loading, and excess Na+ presence. However, 
there would be significantly delay in protein release if chitosan coating were applied 
on the Ca-alginate microcapsules. The release of HA was also confirmed by SDS-
PAGE and Western blotting. The results suggested the potential applications for a 
controlled release of HA antigen for vaccination against H5N1 influenza virus. 
 
5.2 Recommendations for future work 
While my understanding of electrostatic extrusion and alginate matrix formation is 
rapidly increasing, there is still much work to be done for its implementations. 
 
Firstly, the in vivo function of alginate matrix must be studied for antigen delivery 
through alginate matrix in animals. Its effectiveness in vaccination should be 
compared with solo antigen injection and existed antigen delivery vehicles. 
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The stability of alginate matrix should also be improved. The approaches involved 
alginate microcapsules made from crosslinked barium ions would be interesting. 
Barium alginate microcapsules were believed to be chemically and physically more 
stable than calcium alginate microcapsules under both in vitro and in vivo conditions. 
 
My results also reflected a very low antigen encapsulation efficiency, therefore it is 
very important to improve its efficiency before any implementation would be possible. 
Usually, higher polymer concentrations would help improve the encapsulation 
efficiency and minimizing the loss of antigen during microcapsules formation. 
Therefore, study on different polymer concentration would also be crucial.  
 
Finally, scaling-up of this technique is necessary for the manufacturing process. It 
would be quite challenging to improve production capacity while maintaining a 
controlled environment, operational discipline and rigorous quality controls. For 
multiple-needle operation, the breakage force must be applied carefully and uniformly 
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